Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,960.00
Bid: 1,969.00
Ask: 1,971.00
Change: 35.00 (1.82%)
Spread: 2.00 (0.102%)
Open: 1,937.00
High: 1,977.00
Low: 1,931.00
Prev. Close: 1,925.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Circ re. Roxane Acquisition

11 Feb 2016 12:19

RNS Number : 8101O
Hikma Pharmaceuticals Plc
11 February 2016
 

 

 

 

Publication of supplementary circular

 

London, 11 February 2016 - Hikma Pharmaceuticals PLC ("Hikma" or the "Company") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing pharmaceuticals company, has today published a supplementary combined prospectus and circular (the "Supplementary Prospectus") which is a supplement to the combined prospectus and circular published by the Company on 22 January 2016 in relation to the Acquisition and Consideration Shares (the "Prospectus").

 

The publication of the Supplementary Prospectus is a regulatory requirement under the Listing Rules and Prospectus Rules following the announcement made by the Company on 10 February 2016. The Supplementary Prospectus should be read in conjunction with the Prospectus.

 

As required by Listing Rules 9.6.1R and 9.6.3R and Prospectus Rule 3.2.1R and 3.4.3R, a copy of the Supplementary Prospectus has been approved by the Financial Conduct Authority and published and submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/NSM .

 

Posting of the Supplementary Prospectus is expected to be completed on 11 February 2016. You will find enclosed with the Supplementary Prospectus an additional Form of Proxy for use at the General Meeting to assist Shareholders in voting on the Resolutions. Shareholders may return either the original Form of Proxy or the Form of Proxy enclosed with the Supplementary Prospectus. If two or more valid but differing Forms of Proxy are delivered in respect of the same share for use at the General Meeting, the one which is last delivered (regardless of its date, its date of sending or the date of its execution) shall be treated as replacing and revoking the others as regards that share.

 

As set out in the announcement made by the Company on 10 February 2016, the Board continues to unanimously recommend that the Shareholders vote in favour of the Resolutions at the General Meeting, to be held at 9.00a.m. on 19 February 2016 at The Westbury, Bond Street, Mayfair, London W1S 2YF.

 

Capitalised terms used in this announcement have the meanings given to them in the Prospectus. The Prospectus and Supplementary Prospectus are available on the Company's website (www.hikma.com/en/investors/shareholder-services/circular-and-egm.aspx) and may be inspected at the office of the Company's counsel at Slaughter and May, One Bunhill Row, London, EC1Y 8YY.

 

Enquiries

 

Hikma Pharmaceuticals PLC

Peter Speirs, Company Secretary

 

Susan Ringdal, Vice President, Corporate Strategy & Investor Relations

 

 

+44 (0)20 7399 2772

 

+44 (0)20 7399 2760

FTI Consulting

Matthew Cole & Ben Atwell

 

+44 (0)20 3727 1000

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million.

 

Disclaimer

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE A PROSPECTUS OR EQUIVALENT. INVESTORS SHOULD NOT SUBSCRIBE FOR OR PURCHASE ANY SECURITIES REFERRED TO IN THIS ANNOUNCEMENT. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN INVITATION OR OFFER TO SELL OR EXCHANGE OR THE SOLICITATION OF AN INVITATION OR OFFER TO BUY OR EXCHANGE ANY SECURITIES IN THE UNITED STATES OR ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DO SO PRIOR TO REGISTRATION OR QUALIFICATION UNDER THE SECURITIES LAWS OF SUCH JURISDICTION. NONE OF THE SECURITIES REFERRED TO IN THIS ANNOUNCEMENT SHALL BE SOLD, ISSUED, EXCHANGED OR TRANSFERRED IN ANY JURISDICTION IN CONTRAVENTION OF APPLICABLE LAW. THE SECURITIES HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE SECURITIES ACT, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES OR OTHER JURISDICTION AND ARE BEING OFFERED AND SOLD IN RELIANCE UPON AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND ANY APPLICABLE STATE OR LOCAL SECURITIES LAWS. THERE WILL BE NO PUBLIC OFFERING OF SECURITIES IN THE UNITED STATES.

 

CITIGROUP GLOBAL MARKETS LIMITED ("CITI"), WHICH IS AUTHORISED BY THE PRUDENTIAL REGULATION AUTHORITY AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY AND THE PRUDENTIAL REGULATION AUTHORITY, IS ACTING EXCLUSIVELY FOR HIKMA AND NO ONE ELSE IN CONNECTION WITH THE ACQUISITION AND WILL NOT BE RESPONSIBLE TO ANYONE OTHER THAN HIKMA FOR PROVIDING THE PROTECTIONS AFFORDED TO CLIENTS OF CITI OR FOR PROVIDING ADVICE IN RELATION TO THE ACQUISITION OR ANY OTHER MATTERS REFERRED TO IN THIS ANNOUNCEMENT. NEITHER CITI NOR ANY OF ITS DIRECTORS, OFFICERS, REPRESENTATIVES, EMPLOYEES, ADVISERS, AGENTS OR AFFILIATES OWES OR ACCEPTS ANY DUTY, LIABILITY OR RESPONSIBILITY WHATSOEVER (WHETHER IN CONTRACT, IN TORT, UNDER STATUTE OR OTHERWISE) TO ANY PERSON WHO IS NOT A CLIENT OF CITI IN CONNECTION WITH THIS ANNOUNCEMENT, ANY STATEMENT CONTAINED HEREIN, THE ACQUISITION OR OTHERWISE.

 

-- ENDS --

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CIRMMGMZZMRGVZM
Date   Source Headline
30th May 20183:20 pmRNSDirector/PDMR Shareholding
30th May 20189:00 amRNSHikma launches Methylergonovine Maleate Tablets
23rd May 201810:20 amRNSDirector/PDMR Shareholding
18th May 20181:01 pmRNSAGM Results
18th May 20187:00 amRNSTrading Statement
17th May 20181:45 pmRNSDirector/PDMR Shareholding
17th May 20181:10 pmRNSDirector/PDMR Shareholding
15th May 20182:26 pmRNSDirector/PDMR Shareholding
3rd May 20189:00 amRNSHikma launches Methotrexate Injection
1st May 20181:38 pmRNSTotal Voting Rights
26th Apr 20181:40 pmRNSHolding(s) in Company
25th Apr 201810:41 amRNSBlock listing Interim Review
24th Apr 20189:00 amRNSHikma expands licensing agreement with Rovi
20th Apr 20189:00 amRNSHikma launches Dexrazoxane for Injection
19th Apr 201812:00 pmRNSAnnual Financial Report and Notice of AGM
10th Apr 20182:34 pmRNSDirector/PDMR Shareholding
3rd Apr 201811:19 amRNSTotal Voting Rights
29th Mar 20189:00 amRNSHikma launch-Palonosetron Hydrochloride Injection
20th Mar 20189:00 amRNSHikma has launched Ritonavir Tablets USP
19th Mar 20183:50 pmRNSDirector/PDMR Shareholding
14th Mar 20187:00 amRNSFinal Results
12th Mar 20187:00 amRNSUpdate status on ANDA for generic Advair Diskus®
9th Mar 20189:21 amRNSBlock Listing Application
27th Feb 201812:23 pmRNSNotice of Results
20th Feb 20187:00 amRNSSigurdur Olafsson appointed CEO of Hikma
13th Feb 20184:43 pmRNSHolding(s) in Company
8th Feb 201812:41 pmRNSDirector/PDMR Shareholding
8th Feb 201812:39 pmRNSDirector/PDMR Shareholding
8th Feb 201812:37 pmRNSDirector/PDMR Shareholding
26th Jan 20184:56 pmRNSHolding(s) in Company
17th Jan 20185:22 pmRNSHolding(s) in Company
15th Jan 20188:00 amRNSHikma Appoints Dr. Surendera Tyagi
4th Jan 201811:19 amRNSTotal Voting Rights
19th Dec 20179:00 amRNSHikma reaches licensing agreement with Celltrion
13th Dec 20179:00 amRNSHikma- Dihydroergotamine Mesylate Injection, USP
12th Dec 20179:59 amRNSHolding(s) in Company
11th Dec 20179:33 amRNSHolding(s) in Company
1st Dec 20179:28 amRNSTotal Voting Rights
30th Nov 20175:47 pmRNSHikma Ventures- $20.5m Series C round for Prognos
28th Nov 201710:24 amRNSAnnouncement
27th Nov 20171:38 pmRNSHikma Ventures invests in Biolinq
22nd Nov 20179:32 amRNSHolding(s) in Company
20th Nov 20179:32 amRNSHolding(s) in Company
14th Nov 20178:47 amRNSHolding(s) in Company
14th Nov 20177:00 amRNSHikma Acquires Products from Boehringer Ingelheim
8th Nov 20174:45 pmRNSHolding(s) in Company
2nd Nov 20172:51 pmRNSHolding(s) in Company
1st Nov 201711:43 amRNSTotal Voting Rights
30th Oct 20179:26 amRNSHikma launches Pantoprazole Sodium for Injection
5th Oct 20179:49 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.